Table 2

Description of the 13 patients with adverse pregnancy outcomes

Patient numberAgeAPS/SLETreatmentaPL at screeningPregnancy durationAPOs
127SLEASA, HEP (low dose)LAC23.6 WGFetal death
229Thrombotic APSASA, HEP (full dose) IVIGLAC
aCL IgG
aβ2GPI IgG
29.4 WGAtypical HELLP and severe pre-eclampsia
339Thrombotic APSASA, HEP (full dose)
HCQ
LAC
aCL IgG/IgM
aβ2GPI IgG
38.1 WGSGA
438Thrombotic APSASA, HEP (full dose)
HCQ
LAC
aCL IgG
aβ2GPI IgG
17.4 WGFetal death
539SLEASALAC39.2 WGSGA
633Obstetrical APSASA, HEP (full dose)
HCQ
aCL IgG
aβ2GPI IgG
29.3 WGSuperimposed severe pre-eclampsia, IUGR and birth weight <10th percentile
733Obstetrical APSASA, HEP
(low dose)
32.1 WGPre-eclampsia
834Thrombotic APSASA, HEP (full dose)LAC
aCL IgG
aβ2GPI IgG
18.2 WGFetal death
935SLE
thrombotic APS
ASA, HEP (low dose)
HCQ
LAC26.4 WGHELLP
1023Thrombotic APSHEP (full dose)
HCQ
aCL IgG
aβ2GPI IgG
38.2 WGSGA
1132Thrombotic APSHEP (full dose)aCL IgG
aβ2GPI IgG
32.4 WGGestational hypertension, placental insufficiency and SGA
1222SLE
thrombotic APS
HEP (full dose)
Steroids HCQ
LAC
aCL IgG
aβ2GPI IgG
20.3 WGPreterm delivery, fetal demise due to HELLP syndrome
1335Thrombotic APSASA, HEP (full dose)LAC
aCL IgG
17.6 WGFetal death
  • aCL, anticardiolipin antibodies; aPL, antiphospholipid antibodies; APOs, adverse pregnancy outcomes; APS, antiphospholipid syndrome; ASA, aspirin; aβ2GPI, anti-β2 glycoprotein I antibodies; HCQ, hydroxychloroquinine; HELLP, haemolysis elevated liver enzyme and low platelet count syndrome; HEP, low molecular weight heparin; IUGR, intrauterine growth restriction; IVIG, intravenous immunoglobulin therapy; LAC, lupus anticoagulant; SGA, small for gestational age neonate (birth weight below the fifth percentile); SLE, systemic lupus erythematosus; WG, weeks of gestation.